Medical Condition News

RSS

Genzyme introduces new global grant program to support LSD patient community

Genzyme Corporation today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards.

28 Feb 2011

Daytime sleep can have cardiovascular benefits: New research

A daytime sleep could have cardiovascular benefits according to new research by Ryan Brindle and Sarah Conklin, PhD, from Allegheny College in Pennsylvania in the US.

28 Feb 2011

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Omni Bio Pharmaceutical, Inc., an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Free radicals make the heart to beat with the correct force

Fear of free radicals may be exaggerated, according to scientists from the Swedish medical university Karolinska Institutet. A new study, published in the Journal of Physiology, shows that free radicals act as signal substances that cause the heart to beat with the correct force.

28 Feb 2011

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

biOasis Technologies Inc. is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer's disease.

28 Feb 2011

Synageva supports Fourth International Rare Disease Day

Synageva BioPharma Corp., a privately held biopharmaceutical company that is developing therapeutic products for rare disorders, announced today that the company is supporting the Fourth International Rare Disease Day observance on February 28, 2011.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company's patent-pending MEDIHONEY® Gel Wound and Burn Dressing.

28 Feb 2011

FDA approves Matrix Labs generic Neurontin ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Capsules USP, 100 mg, 300 mg and 400 mg, the generic version of Pfizer's Neurontin® Capsules used to treat a painful complication of shingles.

28 Feb 2011

PNH patients urge government to provide access to life-saving treatment

With so few people affected by rare diseases, how does a group of less than 90 patients across Canada make their voices heardon a life-and-death issue such as access to treatment? Barry Katsof, President of the Canadian Association of PNH Patients, says his group is turning to social media to ask others to take a stand with them in the fight for their lives.

28 Feb 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

Wear That You Care. Today is Rare Disease Day and 46NYC is helping raise awareness for an important cause – this time the drug development crisis facing the rare disease patient community worldwide.

28 Feb 2011

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Just in time for Heart Health Month, EcoNugenics introduces CIRCUTOL Cardiovascular Health Support. EcoNugenics has once again demonstrated excellence in being at the forefront of the latest developments in natural alternative health solutions.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Investing in adolescents can help reduce poverty, improve health, UNICEF report says

Additional investment in the world's 1.2 billion adolescents - 88 percent of whom live in the developing world - has the potential to help alleviate inequality and poverty, UNICEF said in its annual State of the World's Children report released on Friday, IRIN reports.

28 Feb 2011

Medical Condition News

Genzyme introduces new global grant program to support LSD patient community

Daytime sleep can have cardiovascular benefits: New research

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Free radicals make the heart to beat with the correct force

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

Synageva supports Fourth International Rare Disease Day

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

FDA approves Matrix Labs generic Neurontin ANDA

PNH patients urge government to provide access to life-saving treatment

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

p53 gene blocks EMT essential to cancer metastasis

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Researchers to examine thrombolysis for treatment of DVT in leg

Investing in adolescents can help reduce poverty, improve health, UNICEF report says

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Latest News